MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

BX471

CAS No. : 217645-70-0

MCE 国际站：BX471

产品活性：BX471 (ZK-811752) 是以一种口服有效的，选择性，非多肽的 CCR1 拮抗剂，K_i 值为 1 nM，对其选择性是对 CCR2，CCR5 和 CXCR4 的 250 倍。

研究领域：GPCR/G Protein  |  Immunology/Inflammation

作用靶点：CCR

In Vitro: BX471 is a potent functional antagonist based on its ability to inhibit a number of CCR1-mediated effects including Ca²⁺ mobilization, increase in extracellular acidification rate, CD11b expression, and leukocyte migration. BX471 demonstrats a greater than 10,000-fold selectivity for CCR1 compared with 28 G-protein-coupled receptors. BX471 is also able to displace ¹²⁵I-MIP-1α/CCL3 binding to mouse CCR1 in a concentration-dependent manner with a K_i of 215±46 nM. Increasing concentrations of BX471 inhibits the Ca²⁺ transients induced by MIP-1α/CCL3 in both human and mouse CCR1 with IC₅₀ of 5.8±1 nM and 198±7 nM, respectively. BX471 (0.1-10 μM) shows a dose-dependent inhibition of RANTES-mediated and shear-resistant adhesion on IL-1β-activated microvascular endothelium in shear flow in isolated blood monocytes. BX471 also inhibits the RANTES-mediated adhesion of T lymphocytes to activated endothelium.

In Vivo: BX471 (4 mg/kg, p.o. or i.v.) is orally active with a bioavailability of 60% in dogs. Furthermore, BX471 effectively reduces disease in a rat experimental allergic encephalomyelitis model of multiple sclerosis. BX471 (20 mg/kg, s.c.) reaches peak plasma levels of 9 μM by around 30 minutes, and this rapidly declines to approximately 0.4 μM after 2 hours. From 4 to 8 hours the drug plasma levels drops to 0.1 μM or lower. Mice treated with 20 mg/kg of BX471 for 10 days shows a reduction of interstitial CD45 positive leukocytes of approximately 55%. BX471 has a borderline significant effect on the number of CCR5-positive CD8 cells in the peripheral blood. BX471 reduces the amount of FSP1-positive cells by 65% in UUO kidneys as compared with vehicle control. Pretreatment witih BX471 reduces macrophage and neutrophil accumulation in kidney after ischemia-reperfusion injury.

相关产品：Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Endocrinology Compound Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  Targeted Diversity Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Chemokine Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  DAPTA  |  BMS-753426  |  BMS-813160  |  JNJ-27141491  |  CCR5 antagonist 2  |  AZD-5672  |  CCR5 antagonist 3  |  Vercirnon  |  GSK2239633A  |  Bindarit  |  Leronlimab  |  Maraviroc  |  Plozalizumab  |  AZD-1678  |  CCR4 antagonist 3-1  |  Aplaviroc hydrochloride  |  CCR1 antagonist 6  |  J-113863  |  CCR1 antagonist 11 hydrochloride  |  AZD2423  |  AZD2098  |  RS102895 hydrochloride  |  LMD-009  |  Carlumab  |  Vicriviroc maleate  |  CKLF1-C19  |  ALK4290  |  CCR1 antagonist 10  |  ZK756326 dihydrochloride  |  INCB 3284 dimesylate

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-12080

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。